{
    "nct_id": "NCT03531814",
    "official_title": "Pilot Study of Medication Adherence in Children, Adolescents, and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials",
    "inclusion_criteria": "* INCLUSION CRITERIA:\n\nInclusion Criteria for Patient\n\n* Patients must be between 3 and 59 years of age at the time of the baseline assessment.\n* Patients must be enrolled on a neurofibromatosis Type 1 (NF1) clinical trial for an oral medication directed at the treatment of plexiform neurofibroma(s) (enrollment on this study to occur ideally within 1st cycle) Patients must have regular access to a computer or electronic device (e.g., smartphone, tablet) with internet access.\n* Must have a parent or adult primary caregiver willing to participate in the study.\n* Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n* Subjects must be able to read and comprehend the English language.\n\nInclusion Criteria for Parents or Caregivers\n\n* Must be a parent or primary caregiver of a child (or if applicable adult patient) of diagnosed with NF1 and enrolled on a clinical trial for oral medication.\n* Must have a child (or if applicable adult patient) willing to participate in the study\n* Must have regular access to a computer or electronic device (e.g., smartphone, tablet) with internet access.\n* Must be able to speak and understand English.\n* Ability of subject to understand and the willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nExclusion Criteria for Patient\n\n* In the opinion of the principal investigator (PI) or an associate investigator (AI), the subject has significant cognitive or emotional difficulties that would prevent them from being able to understand and/or participate fully in the study or complete the measures. Though these patients might be receiving assistance in taking medication from a caregiver, it is likely that their medication taking routine would be significantly different from the general population of patients with NF1.\n* Patients receiving the study drug in liquid form, since the use of medication event monitoring systems (MEMS^TM) caps prohibits liquid dosing.\n\nExclusion Criteria for Parent or Caregiver\n\nNone\nHealthy volunteers allowed\nMust have minimum age of 3 Years\nMust have maximum age of 59 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}